泽璟制药：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定

Core Viewpoint - Zai Lab's investigational product ZG006 has received orphan drug designation from the FDA for the treatment of neuroendocrine cancer, indicating potential for market exclusivity and support in development [1] Group 1: Product Development - ZG006 is currently under development for treating neuroendocrine cancer and has recently achieved orphan drug status from the FDA [1] - Following this designation, the company must continue discussions with the FDA regarding subsequent clinical trials and registration plans for ZG006 [1] - The success of clinical trials, obtaining FDA approval, and the timeline for market entry remain uncertain [1]